Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Common Equity (2016 - 2026)

Biomerica's Common Equity history spans 16 years, with the latest figure at $3.3 million for Q1 2026.

  • On a quarterly basis, Common Equity fell 40.06% to $3.3 million in Q1 2026 year-over-year; TTM through Feb 2026 was $3.3 million, a 40.06% decrease, with the full-year FY2025 number at $4.1 million, down 37.72% from a year prior.
  • Common Equity hit $3.3 million in Q1 2026 for Biomerica, down from $4.4 million in the prior quarter.
  • Over the last five years, Common Equity for BMRA hit a ceiling of $11.7 million in Q2 2023 and a floor of $3.3 million in Q1 2026.
  • Historically, Common Equity has averaged $7.0 million across 5 years, with a median of $6.6 million in 2024.
  • Biggest five-year swings in Common Equity: skyrocketed 40.83% in 2023 and later tumbled 50.35% in 2024.
  • Tracing BMRA's Common Equity over 5 years: stood at $7.2 million in 2022, then increased by 29.53% to $9.4 million in 2023, then crashed by 45.5% to $5.1 million in 2024, then fell by 13.28% to $4.4 million in 2025, then fell by 25.21% to $3.3 million in 2026.
  • Business Quant data shows Common Equity for BMRA at $3.3 million in Q1 2026, $4.4 million in Q4 2025, and $5.2 million in Q3 2025.